EXTEND‐I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration
Authors:
- Masahito OhjiMOMasahito Ohji
- EXTEND-I Study GroupEGEXTEND-I Study Group
- 27 April 2010
- journal article
- research article
- Published by Wiley in Acta Ophthalmologica
- Vol. 88 (3) , 309-316
Abstract
: Purpose: To evaluate the efficacy and safety of intravitreal ranibizumab for subfoveal choroidal neovascularization (CNV) secondary to age‐related macular degeneration (AMD) in Japanese patients.Methods: This open‐label, multicentre, Phase I/II study enroled patients into Group A (single injection of ranibizumab nonrandomized doses of 0.3 or 0.5 mg followed by 11 monthly injections of the same dose) and Group B (12 monthly injections of ranibizumab randomized to 0.3 or 0.5 mg). The primary efficacy endpoint was the mean change from baseline in best‐corrected visual acuity (BCVA) score at Month 6. Safety was evaluated in all patients who received ranibizumab.Results: Of 88 patients enroled, 12 entered Group A (six per dose) and 76 entered Group B (0.3 mg: n = 35; 0.5 mg: n = 41). Mean change from baseline in BCVA was significantly increased for both doses (Group B) at Month 6 (0.3 mg: +8.1 letters, p = 0.0006; 0.5 mg: +9.0 letters, p < 0.0001) and Month 12 (0.3 mg: +9.5 letters, p = 0.0001; 0.5 mg: +10.5 letters, p < 0.0001). At Month 12, one patient (0.3 mg) and 0 patients (0.5 mg) lost ≥15 letters, while 37.1% (0.3 mg) and 31.7% (0.5 mg) of patients gained ≥15 letters. Ocular serious adverse events (SAEs) of the study eye were reported in 1 and 2 patients in the 0.3‐ and 0.5‐mg groups, respectively. Nonocular SAEs were experienced by 2 and 5 patients in the 0.3‐ and 0.5‐mg groups, respectively. No cases of endophthalmitis were reported.Conclusion: Ranibizumab was effective and well tolerated in Japanese patients with subfoveal CNV secondary to AMD.Keywords
This publication has 13 references indexed in Scilit:
- The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degenerationEye, 2008
- Photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD): Results of the Japanese AMD Trial (JAT) extensionJapanese Journal of Ophthalmology, 2008
- Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivoExperimental Eye Research, 2007
- Anxiety and Depression Prevalence Rates in Age-Related Macular DegenerationInvestigative Ophthalmology & Visual Science, 2007
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATIONRetina, 2006
- Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularizationActa Ophthalmologica Scandinavica, 2006
- Impact of age related macular degeneration on quality of lifeBritish Journal of Ophthalmology, 2006
- Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degenerationAmerican Journal of Ophthalmology, 2003